Immunome shares are trading higher after a Form4 filing showed President and CEO Clay Siegall Bought 100,000 shares at an average price of $13.88 per share.
Portfolio Pulse from Benzinga Newsdesk
Immunome shares are trading higher following a Form4 filing that revealed President and CEO Clay Siegall purchased 100,000 shares at an average price of $13.88 per share.
May 21, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunome shares are trading higher after President and CEO Clay Siegall bought 100,000 shares at an average price of $13.88 per share.
The purchase of a significant number of shares by the company's President and CEO is a strong positive signal to the market, indicating confidence in the company's future prospects. This insider buying activity is likely to boost investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100